Loading…
Sai Parenterals (SAIPARENT)₹506.10+4.75%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Sai Parenterals reported sales of ₹179 Cr, up 435.6% from Jun 2025, and net profit of ₹7.94 Cr, up 455.2% year on year. For the year to Mar 2026, sales were ₹382 Cr and net profit ₹14.02 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 33.46 | 96.43 | 199 | 179 |
| Expenses | 28.70 | 99.91 | 172 | 155 |
| Operating Profit | 4.72 | −3.55 | 26.04 | 23.47 |
| OPM % | 14.1% | −3.7% | 13.1% | 13.1% |
| Other Income | 1.18 | 3.14 | 2.89 | 3.75 |
| Interest | 2.45 | 5.39 | 8.37 | 9.33 |
| Depreciation | 1.46 | 5.78 | 8.17 | 8.10 |
| Profit before tax | 1.99 | −11.60 | 12.36 | 9.76 |
| Tax % | 29.4% | −42.7% | −6.2% | 19.0% |
| Net Profit | 1.43 | −6.67 | 13.18 | 7.94 |
| EPS (Rs) | 0.53 | −1.81 | 2.99 | 1.80 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 97.35 | 155 | 164 | 382 |
| Expenses | 78.12 | 122 | 124 | 343 |
| Operating Profit | 18.93 | 31.91 | 38.91 | 38.90 |
| OPM % | 18.9% | 20.9% | 24.0% | 9.9% |
| Other Income | 0.00 | 1.01 | 1.01 | 9.03 |
| Interest | 5.98 | 10.97 | 11.96 | 18.94 |
| Depreciation | 6.01 | 8.99 | 7.99 | 16.99 |
| Profit before tax | 6.98 | 12.97 | 19.93 | 11.96 |
| Tax % | 40.0% | 33.0% | 28.0% | −20.0% |
| Exceptional items | 0.00 | 0.00 | 0.04 | 0.00 |
| Net Profit | 4.01 | 8.02 | 14.04 | 14.02 |
| EPS (Rs) | 6.15 | 6.38 | 5.45 | 3.24 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 7.00 | 12.98 | 12.98 | 21.98 |
| Reserves | 23.95 | 60.81 | 79.70 | 468 |
| Borrowings | 68.89 | 119 | 93.72 | 468 |
| Other Liabilities | 34.16 | 75.31 | 85.38 | 467 |
| Total Liabilities | 134 | 268 | 272 | 1,424 |
| Fixed Assets | 44.03 | 69.98 | 52.97 | 364 |
| CWIP | 2.01 | 0.00 | 0.00 | 213 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 87.96 | 198 | 219 | 847 |
| Inventories | 13.03 | 37.08 | 51.11 | 172 |
| Trade receivables | 61.08 | 127 | 127 | 181 |
| Cash & equivalents | 0.00 | 4.02 | 2.01 | 418 |
| Total Assets | 134 | 268 | 272 | 1,424 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | −13.01 | −30.02 | 33.04 | 93.07 |
| Cash from investing activity | −19.06 | −46.18 | 0.00 | −275 |
| Cash from financing activity | 23.97 | 78.86 | −35.96 | 596 |
| Net cash flow | −8.01 | 2.01 | −2.01 | 416 |
| Capex | 17.01 | 44.04 | 0.00 | 66.11 |
| Free cash flow | −30.07 | −72.19 | 41.08 | −184 |
| CFO / OP % | −53.9% | −93.9% | 86.1% | 253.1% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 231 | 302 | 283 | 173 |
| Inventory days | 82 | 142 | 198 | 258 |
| Days payable | 140 | 203 | 225 | 224 |
| Cash conversion cycle | 175 | 243 | 258 | 209 |
| Working capital days | 20 | 73 | 80 | −160 |
| ROCE % | — | 16.0% | 17.0% | 5.0% |
For the Jun 2026 quarter, Sai Parenterals reported sales of ₹179 Cr, up 435.6% year on year and net profit of ₹7.94 Cr, up 455.2% year on year. The operating margin was 13.1%.
Sai Parenterals' sales for the year to Mar 2026 were ₹382 Cr.
Net profit for the year to Mar 2026 was ₹14.02 Cr. Earnings per share over the same trailing period were ₹3.24.
Sai Parenterals reported borrowings of ₹468 Cr at Mar 2026, against cash and equivalents of ₹418 Cr.
Cash from operations was ₹93.07 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹184 Cr.